| abstract |
Antibodies that bind RAGE and inhibit the binding between RAGE and HMGBl complexed with CpG DNA are disclosed. The antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range conditions characterized by the presence of DNA immune complexes and/or associated with the expression of one or more type-I IFN- inducible gene. |